NA vaccine Institute
- Biotech or pharma, therapeutic R&D
A Seoul-based biotech preclinical and clinical stage company specializes in the ultimate form of TLR3 agonist as a novel immunostimulant for diverse applications, from vaccine adjuvants to vaccine and immunotherapy.
The major pipelines are:
1) Myalgic Encephalomyelitis, chronic fatigue syndrome (ME/CFS) therapy
2) Multiple Sclerosis therapy
3) Zoster vaccine with a safer and stronger IgG and CD4 T-cell response than Shingrix
4) CMV therapeutic vaccine for allogenic Hematopoietic Stem Cell transplantation.
5) Adjuvant therapy for highly metastatic cancer after surgical dissection
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}